Docetaxel-related side effects and their management

Baker, Jackie; Ajani, Jaffer A.; Scotté, Florian; Winther, Dorte; Martín, Miguel; Aapro, Matti; Minckwitz, Gϋnter von

doi:10.1016/j.ejon.2008.10.003

Cited by 216 publications

(147 citation statements)

References 67 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…To identify data in the literature concerning the event under suspicion, the following bibliographic databases were used: the product label, a reference book (Sweetman, 2008) and related articles (Roh et al, 2007;Baker et al, 2008). The temporal analysis of the adverse reactions was determined from direct observations of the drug administration, interviews and medical records.…”

Section: Methodsmentioning

confidence: 99%

Adverse reactions to docetaxel: an active survey

Pereira

Nogueira

Barbosa

et al. 2015

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The rates of breast cancer mortality remain high in Brazil. Docetaxel is a semi-synthetic taxane used to treat various tumors, particularly tumors of the breast, lung and prostate. In this study ADR that occurred in 45 docetaxel users with breast cancer were surveyed. They were identified by type, causality (Naranjo algorithm and World Health Organization categories) and, if considered probable or defined, rated for severity according to SOBRAFO proposal (2007). A total of 325 ADR were observed: 165 in the first, 137 in the second and 23 in the third cycle. Fifty seven ADR were immediate and the others, late. Fatigue and exhaustion for more than five days, classified as Grade 3 by SOBRAFO (2007), were reported as the primary late RAM. There was no significant difference in the occurrence of immediate and late ADR between cycles (p=1 and p=0.3577, respectively). The presence of a pharmacist gave the patients a better understanding of the occurrence of RAM, especially those that occur outside the hospital, between chemotherapy cycles and are often not reported to the healthcare team, creating institutional demands and reaching the goal to track, observe and correlate the RAM for each user.Uniterms: Docetaxel/adverse reactions. Drugs/adverse reactions. Breast Cancer/tretament/reactions.As taxas de mortalidade por câncer de mama no Brasil permanecem altas. O docetaxel é um taxano semi-sintético usado para tratar vários tumores, particularmente tumores da mama, pulmão e próstata. Neste estudo, as Reações Adversas (RAM) ocorridas em 45 pacientes com câncer de mama foram monitoradas. Elas foram classificadas pelo tipo e causalidade (Algoritmo de Naranjo e categorias propostas pela Organização Mundial da Saúde) e, se consideradas prováveis ou definidas, foram classificadas também pela severidade, de acordo com a proposta da SOBRAFO (2007). Um total de 325 RAM foram observadas: 165 no primeiro, 137 no segundo e 23 no terceiro ciclo. Cinquenta e sete RAM foram imediatas e as demais tardias. Fadiga e exaustão por mais de 5 dias, classificadas como grau 3 pela SOBRAFO (2007), foram as principais RAM encontradas. Não houve diferença significativa na ocorrência de RAM imediatas ou tardias entre os ciclos (p=1 e p=0,3577, respectivamente). A presença de um farmacêutico proporcionou aos pacientes um melhor entendimento sobre a ocorrência de RAM, especialmente sobre aquelas que ocorrem fora do ambiente hospitalar, entre os ciclos da terapia, não sendo usualmente relatadas aos profissionais de saúde. Isto gerou uma demanda na instituição e permitiu alcançar a meta de acompanhar, observar e correlacionar as RAM de cada paciente.Unitermos: Docetaxel/reações adversas. Medicamentos/reações adversas. Câncer de mama/tratamento/ reações.

show abstract

Section: Methodsmentioning

confidence: 99%

Adverse reactions to docetaxel: an active survey

Pereira

Nogueira

Barbosa

et al. 2015

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…It has been reported that DTX is more effective and safer than paclitaxel (Grant et al, 2003). Unfortunately, despite these advantages, clinical use of DTX is still limited due to its low water solubility and serious adverse effects, including neutropenia, peripheral neuropathy and hypersensitivity reactions (Engels et al, 2005;Izquierdo et al, 2006;Baker et al, 2009). It has been reported that the toxicity is closely related to formulation (Rowinsky, 1997;Immordino et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

Docetaxel-loaded liposomes: preparation, pH sensitivity, Pharmacokinetics, and tissue distribution

Zhang

Xia

et al. 2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Docetaxel (DTX), as a member of taxoid family, has been widely used in the treatment of cancers. The present study prepared pH-sensitive DTX-loaded liposomes (DTX-Lips) by thin-film dispersion method and various physico-chemical and morphological properties were examined. The pH sensitivity of in vitro DTX release and the in vivo pharmacokinetics and tissue distribution using Kunming mice were also investigated. The mean particle size and zeta potential of DTX liposomes were (277±2) nm and (−32.60±0.26) mV, respectively. Additionally, in vitro drug release study showed that the cumulative release rate was 1.3 times more at pH 5.0 than at pH 7.4, suggesting a pH-dependent release ability of DTX-Lips. Pharmacokinetic and pharmaceutical studies in comparison with Duopafei ® showed that the half-time period (t 1/2 ) and area under the curve (AUC) of DTX-Lips in mouse plasma were 1.8 times longer and 2.6 times higher, respectively, and that DTX-Lips selectively accumulated in macrophage-rich organs such as liver and spleen. These results together suggest that the DTX-Lips could be a promising formulation for the clinical administration of DTX.

show abstract

“…However, the use of high-dose docetaxel induce significant toxicities such as asthenia, neuropathy, vertigo and tinnitus (Sarafraz and Ahmadi, 2008;Baker et al, 2009), whereas lowdose of docetaxel have no significant antitumor activity in patients (Ryan et al, 2002).…”

Section: Fig 1 Structure Of Thiacremonone (A) and Docetaxel (B)mentioning

confidence: 99%

Anti-Cancer Effect of the Combination of Thiacremonone and Docetaxel by Inactivation of NF-κB in Human Cancer Cells

Ban¹,

Cho²,

Hwang³

et al. 2009

Biomolecules and Therapeutics

View full text Add to dashboard Cite

-Thiacremonone, the main component isolated from heated garlic (Allium sativum L.), is interested for using as a cancer preventive or therapeutic agent since garlic has been known to be useful plant in the treatment of cancers. Nuclear factor kappaB (NF-κB) is constitutively activated in the prostate cancer and activation of NF-κB is implicated in drug resistance in cancer cells. Docetaxel, a semisynthetic analog of paclitaxel, is an antineoplastic drug widely used for advanced various cancer. In previous studies, we found that thiacremonone inhibited activation of NF-κB in cancer cells and marcrophages. In the present study, we investigated whether thiacremonone could increase susceptibility of prostate cancer cells (PC-3 and DU145) to docetaxel via inactivation of NF-κB. We found that the combination treatment of thiacremonone (50 μg/ml) with docetaxel (5 nM) was more effective in the inhibition of prostate cancer cell growth and induction of apoptosis accompanied with the significant inhibition of NF-κB activity than those by the treatment of thiacremonone or docetaxel alone. It was also found that NF-κB target gene expression of Bax, caspase-3 and caspase-9 was much more significantly enhanced, but the expression of Bcl-2 was also much more significantly inhibited by the combination treatment. These results indicate that thiacremonone inhibits NF-κB, and enhances the susceptibility of prostate cancer cells to docetaxel. Thus, thiacremonone could be useful as an adjuvant anti-cancer agent.

show abstract

Docetaxel-related side effects and their management

Cited by 216 publications

References 67 publications

Adverse reactions to docetaxel: an active survey

Adverse reactions to docetaxel: an active survey

Docetaxel-loaded liposomes: preparation, pH sensitivity, Pharmacokinetics, and tissue distribution

Anti-Cancer Effect of the Combination of Thiacremonone and Docetaxel by Inactivation of NF-κB in Human Cancer Cells

Contact Info

Product

Resources

About